Administrative Core

行政核心

基本信息

  • 批准号:
    10704708
  • 负责人:
  • 金额:
    $ 24.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-14 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Administrative Core The Administrative Core is responsible for the overall leadership, management, and execution of the ROBIN center, and it will provide overall organizational, administrative, scientific and clinical management. The Administrative Core will oversee and coordinate all ROBIN program components and centrally monitor and evaluate their performance. In addition, the Administrative Core will facilitate all interactions with the External Advisory Board (EAB), the Steering Committee, and the other sites of the national ROBIN program. This ROBIN center involves 3 institutions (Cleveland Clinic, Emory University, and Case Western Reserve University), with multiple enrollment sites (Cleveland Clinic system, Cleveland Clinic Florida system, Emory University system) across 2 NCI-designated Comprehensive Cancer Centers (Case Comprehensive Cancer Center, Emory Cancer Center), with representation across these institutions as project and core leaders. The Administrative Core personnel will be led by Drs. Chan, Yu, and Scott, with collaboration from the trial and project leads. Both Drs. Chan and Yu (ROBIN PIs) have extensive experience in managing multi-institution clinical trial and laboratory-based research programs. The specific aims for the Administrative Core are as follows. In Aim 1, the Core will provide all organizational, administrative, educational, and scientific coordination for the ROBIN center projects and cores by cultivating and promoting the ROBIN team through innovation and excellence, collaboration, leveraging resources, and providing constructive feedback. In Aim 2, the Core will provide centralized administrative management for all fiscal aspects of the ROBIN center, including but not limited to clinical trial execution, accounting of grant funds, progress reports, communication, meeting scheduling and minutes, and manuscript and grant preparation. In Aim 3, the Core will evaluate research progress through oral and written documentation, with regular input from the EAB, Steering Committee, and National Cancer Institute (NCI) leadership to ensure that each project meets its objectives within the proposed time frame and to facilitate interactions with other ROBIN sites for trans-ROBIN center projects. In Aim 4, the Core will ensure integration across ROBIN components, including projects and cores, across all sites, and provide interaction through scientific exchanges, coordination of an annual scientific retreat, and through training and development plans that will ensure state-of-the-art practices. In Aim 5, the Core will ensure and monitor best practices for human subjects and animal research for all ROBIN center projects and cores as well as clinical and data operations, and to ensure adequate human and animal biospecimens for all projects (with the Translational and Clinical Correlates Core).
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Timothy An-thy Chan其他文献

Timothy An-thy Chan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Timothy An-thy Chan', 18)}}的其他基金

Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
基因组和微环境决定因素、时间动态以及基于放射的联合疗法的治疗效果
  • 批准号:
    10746700
  • 财政年份:
    2023
  • 资助金额:
    $ 24.74万
  • 项目类别:
Project 3 Molecular Mechanisms Underlying Therapy Response to Radiation and Immune Checkpoint Blockade
项目 3 辐射和免疫检查点封锁治疗反应的分子机制
  • 批准号:
    10818969
  • 财政年份:
    2022
  • 资助金额:
    $ 24.74万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10916639
  • 财政年份:
    2022
  • 资助金额:
    $ 24.74万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10916640
  • 财政年份:
    2022
  • 资助金额:
    $ 24.74万
  • 项目类别:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
基因组和微环境决定因素、时间动态以及基于放射的联合疗法的治疗效果
  • 批准号:
    10875876
  • 财政年份:
    2022
  • 资助金额:
    $ 24.74万
  • 项目类别:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
基因组和微环境决定因素、时间动态以及基于放射的联合疗法的治疗效果
  • 批准号:
    10704661
  • 财政年份:
    2022
  • 资助金额:
    $ 24.74万
  • 项目类别:
Genomic and Microenvironmental Determinants, Temporal Dynamics, and Treatment Efficacy of Radiation-Based Combination Therapies
基因组和微环境决定因素、时间动态以及基于放射的联合疗法的治疗效果
  • 批准号:
    10526300
  • 财政年份:
    2022
  • 资助金额:
    $ 24.74万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10526301
  • 财政年份:
    2022
  • 资助金额:
    $ 24.74万
  • 项目类别:
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
项目 1 Sacituzumab 联合放射治疗膀胱癌的遗传和免疫机制
  • 批准号:
    10704713
  • 财政年份:
    2022
  • 资助金额:
    $ 24.74万
  • 项目类别:
Project 1 Genetic and Immunologic Mechanisms Underlying Combination Sacituzumab plus Radiation Therapy for Bladder Cancer
项目 1 Sacituzumab 联合放射治疗膀胱癌的遗传和免疫机制
  • 批准号:
    10526303
  • 财政年份:
    2022
  • 资助金额:
    $ 24.74万
  • 项目类别:

相似海外基金

Development of a Drosophila-based platform to replace and reduce animal experimentation in epilepsy research
开发基于果蝇的平台来取代和减少癫痫研究中的动物实验
  • 批准号:
    NC/V001051/1
  • 财政年份:
    2020
  • 资助金额:
    $ 24.74万
  • 项目类别:
    Research Grant
Doctoral Dissertation Research: Ethical Issues in Animal Experimentation
博士论文研究:动物实验的伦理问题
  • 批准号:
    1424484
  • 财政年份:
    2014
  • 资助金额:
    $ 24.74万
  • 项目类别:
    Standard Grant
Animal Experimentation Core
动物实验核心
  • 批准号:
    7665015
  • 财政年份:
    2008
  • 资助金额:
    $ 24.74万
  • 项目类别:
Core--Animal Experimentation
核心——动物实验
  • 批准号:
    7422298
  • 财政年份:
    2007
  • 资助金额:
    $ 24.74万
  • 项目类别:
Animal Experimentation Core
动物实验核心
  • 批准号:
    7502321
  • 财政年份:
    2007
  • 资助金额:
    $ 24.74万
  • 项目类别:
Tissue formation involving stem/progenitor cell research and animal experimentation (N01)
涉及干/祖细胞研究和动物实验的组织形成(N01)
  • 批准号:
    30245585
  • 财政年份:
    2006
  • 资助金额:
    $ 24.74万
  • 项目类别:
    Collaborative Research Centres
Core--Animal Experimentation
核心——动物实验
  • 批准号:
    7312565
  • 财政年份:
    2006
  • 资助金额:
    $ 24.74万
  • 项目类别:
Animal experimentation and cardiac phenotyping of transgenic mouse models
转基因小鼠模型的动物实验和心脏表型分析
  • 批准号:
    13327687
  • 财政年份:
    2005
  • 资助金额:
    $ 24.74万
  • 项目类别:
    Research Units
Animal Experimentation system as an infrastructure to support translational progression of diabetes research to medical practice
动物实验系统作为支持糖尿病研究向医学实践转化的基础设施
  • 批准号:
    17200029
  • 财政年份:
    2005
  • 资助金额:
    $ 24.74万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Core--Animal Experimentation
核心——动物实验
  • 批准号:
    6892955
  • 财政年份:
    2005
  • 资助金额:
    $ 24.74万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了